je.st
news
Aradigm Co. (ARDM) Downgraded to "Sell" at Zacks Investment Research
2016-03-24 14:49:09| Biotech - Topix.net
According to Zacks, "Aradigm Corp. is a leading developer of advanced pulmonary drug delivery systems for the treatment of systemic conditions as well as lung diseases. Their hand-held AERx platform is being designed for the rapid and reproducible delivery of a wide range of pharmaceutical drugs and biotech compounds via the lung.
Tags: research
sell
investment
downgraded
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||